FilingReader Intelligence
Livzon Pharmaceutical wins drug approval, continues share buybacks
August 15, 2025 at 05:25 PM UTC•By FilingReader AI
Livzon Pharmaceutical Group received marketing application acceptance from China's NMPA for JP-1366 tablets, an innovative treatment for reflux esophagitis. Phase III trials showed the drug was non-inferior to Nexium.
The company also repurchased 110,300 A shares for RMB4.39 million as part of its ongoing buyback program.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SZSE:000513•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Livzon Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime